Sosei Heptares says it will continue to develop its early-stage oral GPR35 agonistGPR35 agonist after GSK gave the drug back following a decision to stop its own work on the candidate. Sosei Heptares first licensed the candidate to GSK in 2020 and both companies have since worked on preclinical development. But talks have now begun to return the drug fully to Sosei after changes to GSK’s immunology research strategy and leadership. The company added that the transfer of the license had nothing to do with preclinical data from the candidate. Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
BECOME A PREMIUM SUBSCRIBER